ArticleEJHaem2024

Real-life effectiveness of carfilzomib in patients with relapsed multiple myeloma receiving treatment in the context of early access: The CARMYN study.

Kamel Laribi et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.